Critical Care Medicine
Acute myocardial infarction
Acute coronary syndrome
1. Description of the problem
Chest pain may be the result of any number of pathologic and non-pathologic processes. It is important to take a thorough history, as this can often be the key factor in determining the etiology for a patient's chest pain symptoms.
Careful attention should be focused on obtaining a history that may help to establish a diagnosis for the patient's chest pain. Key features of the history include character and quality of the chest pain, location and radiation of the chest pain, precipitating/exacerbating/alleviating factors, chest pain duration, and associated symptoms.
With the history and physical examination, along with ancillary studies (including electrocardiogram, chest x-ray, and laboratory studies), the treating clinician should focus on determining the etiology of symptoms. In particular, one should determine if any high-risk conditions are present, including acute myocardial infarction, acute coronary syndrome, acute pulmonary embolism, pneumothorax, or aortic dissection.
2. Emergency Management
Management largely depends upon the etiology of a patient's chest pain presentation. As in all patients, early management should address hemodynamic stabilization and airway control as necessary. The goal is to evaluate and exclude the possibility of life-threatening diseases, including acute coronary syndrome, pulmonary embolism, and aortic dissection, in particular.
All patients with a history and/or examination concerning for acute myocardial infarction or acute coronary syndrome should get an immediate 12-lead ECG. Patients with possible pneumothorax should have an immediate chest x-ray, or tube thoracostomy if tension pneumothorax is present. Patients with presumed pulmonary embolism often require a confirmatory test, including ventilation-perfusion scan or computed tomography angiography (CTA). Those with possible aortic dissection should be further evaluated with either computed tomography or echocardiography.
Drugs and dosages
Aspirin: Aspirin should be given to all patients with presumed myocardial infarction or acute coronary syndrome; 162-325 mg orally.
Heparin: Either unfractionated or low-molecular-weight heparin should be administed to patients with presumed pulmonary embolism.
As mentioned, an accurate and thorough history is often the key to establishing a definitive diagnosis in patients presenting with chest pain. Ancillary studies, depending upon the pre-test probability of disease, could include ECG, chest x-ray, echocardiogram, computed tomography, or angiography. Other studies often include routine laboratory tests (complete blood count, serum chemistries, creatinine, blood urea nitrogen, liver function tests, cardiac enzymes, d-dimer).
The careful accumulation of data from the history, physical examination, and ancillary studies should help the clinician establish a definitive diagnosis. Often, no diagnosis is determined.
The pathophysiology of chest pain depends upon the exact etiology.
Chest pain is the presenting symptom in over 10% of emergency department visits.
Special considerations for nursing and allied health professionals.
What's the evidence?
Woo, KM. "High-risk chief complaints I: chest pain - the big three". Emerg Med Clin North Am. vol. 27. 2009. pp. 685-712.Overview of chest pain evaluation in the emergency department
Hess, EP. "Derivation of a clinical decision rule for chest radiography in emergency department patients with chest pain and posssible acute coronary syndrome". CJEM. vol. 12. 2010. pp. 128-34.Decision pathway used to differentiate ischemic from non-ischemic causes of chest pain in the emergency department.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC